Injective price prediction: Downtrend persists even after upgrade news? INJ falls 7.14%

Injective price prediction: Downtrend persists even after upgrade news? INJ falls 7.14%
Injective falls 7.14% today to $3.19

Injective (INJ) is trading at $3.19, sitting slightly below both the MA-20 at $3.23 and well under the MA-50 at $4.13 and MA-200 at $8.08, indicating bearish pressure across short, medium, and long-term trends. The Ichimoku Kijun is at $3.58, representing immediate resistance above the current price.

INJ price prediction
24H -1.66%
$4.73
48H -2.49%
$4.69
7D -2.29%
$4.7
1M 7.48%
$5.17
3M 138.25%
$11.46
6M 107.69%
$9.99
12M 87.73%
$9.03
Current price: $ 4.81 0.45 10.32%
Real-time Data 05:08
Daily range 4.84 Arrow from to Icon 4.97
Weekly range 4.04 Arrow from to Icon 5.13
Loading...

Highlights

  • Injective introduced a dynamic INJ gas fee mechanism via a chain upgrade to optimize revenue and reduce on-chain user costs.
  • This upgrade aims to improve transaction efficiency by making gas fees more responsive to network demand, supporting Injective's ongoing protocol evolution.
  • INJ trades at $3.19 below MA-20/MA-50/MA-200, with immediate resistance at $3.58 and a base case range of $2.90–$3.40 amid persistent bearish momentum.

Dynamic gas fee upgrade drives protocol evolution and user efficiency

Injective has introduced a new chain upgrade featuring a dynamic INJ gas fee mechanism aimed at optimizing revenue generation and reducing costs for all on-chain users. This enhancement is designed to improve transaction efficiency and make gas fees more responsive to network demand, enhancing the user experience across the ecosystem. The update highlights Injective’s continued effort to drive adoption and support its protocol’s evolution.

Injective asset chart
Injective price dynamics. Source: TradingView.

Bearish momentum dominates as intraday signals confirm weak sentiment

Momentum is weak, with the MACD flashing a strong sell and the ADX on the daily chart indicating buyers retain some strength but not enough to offset prevailing downside momentum; weekly MACD and RSI are also firmly bearish. The RSI sits at 45.47 on the daily and 30.86 on the weekly, suggesting the asset is approaching but not yet in oversold territory, while the Stochastic RSI and CCI give neutral to oversold signals, highlighting mixed short-term sentiment. Bull/Bear Power signals mild buyer advantage, but the daily change of 7.14% down with no gap at the open and the current price near today’s low underscores persistent selling pressure, high intraday volatility, and a clear trend of weakness since the session started. Intraday momentum signals and price action broadly confirm each other, though there is some divergence between oversold/neutral oscillators and bearish momentum.

Sideways to lower price bias as upside reversal remains unlikely

For the next five trading days, the expected price range is adjusted to $2.90 – $3.40 to reflect typical volatility relative to current levels. There is a very low probability (less than 20%) of a significant price increase, making a further decline the more likely outcome. In the baseline scenario, INJ moves sideways between $2.90 and $3.40. A bullish reversal would require a sustained break above the $3.58 Ichimoku Kijun resistance, while a drop below $2.90 may accelerate further losses.

Anton Kharitonov, expert at Traders Union, sees Injective facing persistent technical weakness across all major timeframes. He notes that bearish momentum persists, with key resistance at $3.58 and daily volatility signaling ongoing downside pressure. Recent chain upgrades show effort to boost protocol value, but have yet to shift sentiment or fundamentals decisively. "Base case remains range-bound between $2.90 and $3.40 — unless $3.58 is reclaimed, I see no strong reason to turn bullish at this stage."

Previously it was reported that INJ attempted recovery from a sustained downtrend, with price consolidating below all major moving averages and immediate resistance identified near $3.5 to $3.65. Momentum remains neutral, with RSI at 47.37, as price tests key levels and a move above the 20-day EMA would signal stabilization, while a break below immediate support could see further downside risk.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.